PharmaTher Inc., pharmaceutical company, engages in repurposing psychedelic-derived drugs using artificial intelligence platform. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Newscope Capital's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PHRM is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 68% a week.
Volatility Over Time: Insufficient data to determine PHRM's volatility change over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how PHRM performed against the Canadian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how PHRM performed against the Canadian Market.
Long-Term Price Volatility Vs. Market
How volatile is Newscope Capital's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Newscope Capital undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PHRM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PHRM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: Insufficient data to calculate PHRM's PE Ratio to determine if it is good value compared to the CA Pharmaceuticals industry average.
PE vs Market: Insufficient data to calculate PHRM's PE Ratio to determine if it is good value compared to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PHRM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PHRM is overvalued based on its PB Ratio (19.4x) compared to the CA Pharmaceuticals industry average (1.5x).
How is Newscope Capital forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Newscope Capital has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Newscope Capital's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Newscope Capital competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Newscope Capital performed over the past 5 years?
Historical Pharmaceuticals & Biotech annual earnings growth
Earnings and Revenue History
Quality Earnings: PHRM is currently unprofitable.
Growing Profit Margin: PHRM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if PHRM's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare PHRM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHRM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-45%).
Return on Equity
High ROE: PHRM has a negative Return on Equity (-37.64%), as it is currently unprofitable.
How is Newscope Capital's financial position?
Financial Position Analysis
Short Term Liabilities: PHRM's short term assets (CA$390.4K) exceed its short term liabilities (CA$10.7K).
Long Term Liabilities: PHRM has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: PHRM is debt free.
Reducing Debt: PHRM has not had any debt for past 5 years.
Debt Coverage: PHRM has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: PHRM has no debt, therefore coverage of interest payments is not a concern.
What is Newscope Capital current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PHRM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PHRM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PHRM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PHRM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PHRM's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Fabio Chianelli (42 yo)
Mr. Fabio Chianelli is the Founder of Newscope Capital Corporation (formerly known as PharmaTher Inc.). and serves as its CEO & Director. He had been the President of Revive Therapeutics Ltd. since July 20...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: PHRM only recently listed within the past 12 months.
Newscope Capital Corporation's company bio, employee growth, exchange listings and data sources
- Name: Newscope Capital Corporation
- Ticker: PHRM
- Exchange: CNSX
- Founded: 2020
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$10.339m
- Shares outstanding: 48.09m
- Newscope Capital Corporation
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PHRM||CNSX (Canadian National Stock Exchange)||Yes||Common Shares||CA||CAD||Oct 2020|
|PHRR.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Oct 2020|
PharmaTher Inc., pharmaceutical company, engages in repurposing psychedelic-derived drugs using artificial intelligence platform. The company was incorporated in 2020 and is based in Toronto, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/27 00:44|
|End of Day Share Price||2020/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.